Rekombinanter IL4 (Pascolizumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter IL4 (Pascolizumab Biosimilar) Antikörper (ABIN7675777)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Expressionssystem
- CHO Cells
-
Verwendungszweck
- Anti-IL-4 Reference Antibody (pascolizumab)
-
Sequenz
- QVTLRESGPA LVKPTQTLTL TCTFSGFSLS TSGMGVSWIR QPPGKGLEWL AHIYWDDDKR YNPSLKSRLT ISKDTSRNQV VLTMTNMDPV DTATYYCARR ETVFYWYFDV WGRGTPVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K,DIVLTQSPSS LSASVGDRVT ITCKASQSVD YDGDSYMNWY QQKPGKAPKL LIYAASNLES GIPSRFSGSG SGTDFTFTIS SLQPEDIATY YCQQSNEDPP TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
-
Produktmerkmale
- Anti-IL-4 Reference Antibody (pascolizumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Reinheit
- >95 %
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
Therapeutic Agents by Target and Mechanism: IL-4 inhibitors
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- +4°C,-80°C
-
-
- IL4 (Pascolizumab Biosimilar)
-
Andere Bezeichnung
- IL-4 (Pascolizumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Molekulargewicht
- 145.5 kDa
-
UniProt
- P05112
Target
-